2023
Lenacapavir: a twice-yearly treatment for adults with multidrug-resistant HIV infection and limited treatment options
Tuan J, Ogbuagu O. Lenacapavir: a twice-yearly treatment for adults with multidrug-resistant HIV infection and limited treatment options. Expert Review Of Anti-infective Therapy 2023, 21: 565-570. PMID: 37067160, DOI: 10.1080/14787210.2023.2203913.Peer-Reviewed Original ResearchConceptsTreatment optionsMultidrug-resistant HIV infectionMultidrug-resistant HIVTreatment-emergent resistanceLimited treatment optionsClinical trial dataDrug-drug interactionsBreakthrough therapy designationHIV-1 capsid inhibitorsMechanism of actionAdherence supportCompanion drugsAntiretroviral agentsHIV infectionHIV treatmentClinical trialsLenacapavirPharmacodynamic propertiesDrug AdministrationExpert opinion sectionCapsid inhibitorsTrial dataU.S. FoodClinical usesYearly treatment
2019
Analysis of the Impact of Antiretroviral Drug Changes on Survival of Patients with Advanced-Stage AIDS with Multidrug-Resistant HIV Infection
Ma R, Jung TH, Peduzzi PN, Brown ST, Kyriakides TC. Analysis of the Impact of Antiretroviral Drug Changes on Survival of Patients with Advanced-Stage AIDS with Multidrug-Resistant HIV Infection. Journal Of The International Association Of Providers Of AIDS Care (JIAPAC) 2019, 18: 2325958219849101. PMID: 31272313, PMCID: PMC6748500, DOI: 10.1177/2325958219849101.Peer-Reviewed Original ResearchConceptsDrug changesCox proportional hazards regression modelKaplan-Meier survival techniqueMultidrug-resistant HIV infectionProportional hazards regression modelsAdvanced-stage AIDSDrug regimen changesSurvival of patientsHazards regression modelsAntiretroviral clinical trialsClinical biomarker dataCause mortalityMedication changesARV regimenHIV infectionImproved survivalRegimen changeClinical outcomesNonclinical reasonsClinical trialsBiomarker changesTreatment historyMultidrug resistanceTherapy strategiesPatients
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply